Top Pharmaceutical Companies in Toronto (63)
Piramal Group is an Indian multinational conglomerate with a presence across healthcare, life sciences, drug discovery, financial services, alternative investment, and real estate.
IPS-Integrated Project Services, LLC, a Berkshire Hathaway company, is a global leader in developing innovative solutions for the consulting, architecture, engineering, project controls, procurement, construction management, and CQV of technically complex facilities worldwide. With technical expertise spanning R&D to pilot-scale to large-scale production, our team specializes in the technology, trends, and regulatory environment to successfully deliver capital projects and improve...
Canada's online pharmacy ?? We make it easy to fill prescriptions ?, consult with pharmacists ?, and order medications online ?. #Pocketpills #PocketpillsPeople
Lash Group is a patient support services company and a pharmaceutical solutions organization that provides services such as reimbursement support, co-pay assistance, and adherence programs to facilitate patient access to therapies.
Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. More than 52,000 employees serve over 130 markets in the three business...
LMC Healthcare is Canada's largest specialist care provider in diabetes and endocrinology. The company transforms diabetes care by making it more accessible, comprehensive, and patient-centric. Operating 11 multi-disciplinary centers of excellence across Ontario and Alberta, LMC provides integrated services including endocrinology specialist practice, diabetes education, pharmacy, chiropody, optometry, and mental health services to over 77,000 patients annually.
MedMe is building the operating system for the pharmacies of the future, powering their transformation from dispensaries to community healthcare hubs. Our mission is to build an all-in-one cloud-based platform that empowers pharmacists to schedule, document, and manage clinical services at scale. Our clients include the 2 largest pharmacy chains in Canada, servicing 3000+ pharmacies, and powering over ~14M patient...
Insulet Corporation, headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod® Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the...
Insulet's Top Stability & Growth Strengths
Strong Revenue Growth: Company reported accelerating revenue growth across 2024–2025 and guided continued double‑digit expansion for 2026. Quarterly updates highlighted broad‑based momentum in both U.S. and international markets.
Strong Market Position & Advantage: Omnipod leads the tubeless/patch‑pump segment and ranked No. 1 in new customer starts in the U.S. and Europe in 2024–2025, reinforcing competitive momentum. First‑to‑market AID clearance for adults with type 2 diabetes and broad CGM integrations bolster positioning.
Market Expansion: International rollouts and expansion into type 2 diabetes materially increased the addressable market and active user base. Added manufacturing capacity in Malaysia supports global demand and cost scaling.
Thornhill Medical, established in 2004, is an innovator, designer and manufacturer of mobile medical technology for military, emergency, disaster, and extreme environments. With over 40 patents awarded or pending, Thornhill Medical is internationally recognized as a leader in the precise control and management of arterial blood gases. Known for innovative medical devices, steeped in science, such as MOVES® SLC™, MADM™,...
.jpg){kind=logo}
Founded in Toronto in 2015, BenchSci is an AI-powered drug discovery platform helping scientists decode biology faster and advance from target to candidate with evidence they can trust. As drug discovery research becomes increasingly fragmented across thousands of data sources, more than 700 models, and hundreds of software tools, BenchSci’s agentic research environment, EMET, brings data, models, software, and scientific reasoning...
Mundipharma is a global healthcare company with a presence across Africa, Asia Pacific, Canada, Europe, Latin America, and the Middle East. Mundipharma is dedicated to bringing innovative treatments to patients in the areas of Pain Management, Infectious Disease and Consumer Healthcare as well as other severe and debilitating disease areas. Our guiding principles, centred around Integrity and Patient-Centricity, are at the heart...
Mundipharma's Top Stability & Growth Strengths
Product Line Growth: Recent approvals and a full asset acquisition for REZZAYO/rezafungin, alongside active Phase 3 work, indicate a broadening portfolio. Lifecycle updates such as a lower‑GWP flutiform MDI reinforce continued product development.
Market Expansion: EU, UK and UAE regulatory clearances and initial availability/reimbursement steps for REZZAYO suggest ongoing rollout into new markets. A multi‑region ex‑U.S. footprint supports selective country‑level leadership in defined niches.
Future-Ready Strategy: The divestment of Consumer Health to focus on prescription specialty care signals a deliberate resource shift toward higher‑value Rx categories. Sustainability initiatives and late‑stage clinical investment point to preparation for evolving market and regulatory expectations.
Pioneering next-gen precision therapeutics for diseases stemming from microtubule dysfunction, such as neuropathies and cardiovascular diseases.
Edwards Lifesciences (NYSE: EW), is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. We thrive on discovery and expanding the boundaries of medical technology, serving patients in 100+ countries, with the help of our employees in areas including Clinical Affairs, Quality Engineering, Research & Development, Regulatory Affairs, Sales &...
Edwards Lifesciences's Top Stability & Growth Strengths
Strong Market Position & Advantage: Edwards is broadly characterized as the TAVR category leader anchored by the SAPIEN portfolio, and its first-to-approval EVOQUE tricuspid replacement reinforces leadership across structural heart. Industry trackers and company updates point to durable share and breadth across aortic, mitral, and tricuspid therapies.
Strong Revenue Growth: Recent results show double-digit top-line expansion and successive raises to the 2026 sales outlook, driven by steady TAVR demand and rapid TMTT growth. Management commentary emphasizes continued momentum with a consistent long-term growth ambition.
Innovation-Driven Growth: First-to-approval EVOQUE in tricuspid replacement, rapid uptake of PASCAL in mitral repair, and extensive long-term SAPIEN evidence position the portfolio for further adoption. Regulatory and policy catalysts, including a pending CMS TAVR coverage reconsideration and accumulating durability data, may expand access.
AtomVie Global Radiopharma is a radiopharmaceutical contract development and manufacturing organization (CDMO) spun out of the Centre for Probe Development and Commercialization. It supports radiotherapeutic programs from clinical development through commercial supply, providing cGMP manufacturing and global distribution alongside scientific, technical, regulatory, quality, and logistics expertise. The company’s work enables development and delivery of radiopharmaceuticals for disease diagnosis and treatment.
Quanticate is a leading global data focused clinical research organisation (CRO) primarily focused on the management, analysis and reporting of data from clinical trials and post-marketing surveillance. As experts in clinical data, Quanticate provides high quality teams that offer efficient outsourcing solutions for: • Clinical Data Management • Biostatistics • SAS Programming • Data quality oversight via Centralized Statistical Monitoring • Medical writing • Pharmacovigilance Quanticate can offer study level support, functional service provision...
Cencora is a leading pharmaceutical solutions organization centered on improving the lives of people and animals everywhere. With 46,000+ global team members, we have the opportunity to make a positive impact on healthcare in communities everywhere. Our team members are empowered to activate their careers through a collective of tools and resources designed to support individual career interests and...
Cencora's Top Stability & Growth Strengths
Profitability: Results show operating income and earnings per share growing faster than sales, and management raised its adjusted EPS outlook. This pattern suggests improving mix and efficiency even within a low‑margin distribution model.
Market Expansion: Investment in the U.S. distribution network and expansion into specialty healthcare via acquisitions (e.g., OneOncology and retina care) indicate a broader growth footprint. Growth in both U.S. and international segments reinforces the company’s reach.
Resilient & Sustainable Growth: Revenue continues to rise across recent fiscal periods, while profit growth outpaces sales. Feedback suggests specialty pharmaceuticals and healthcare services are providing more durable momentum.
EVERSANA is the provider of global services to the life science industry.
EVERSANA's Top Stability & Growth Strengths
Strong Market Position & Advantage: Evidence indicates EVERSANA maintains a strong market position through its integrated, end-to-end commercialization model and a top-tier agency network. Feedback suggests exclusive launch mandates and consistent MM+M top‑10 agency rankings reinforce this competitive advantage.
Innovation-Driven Growth: Feedback suggests the company is investing in AI-enabled and software-driven offerings, including an AI Accelerator, an AI-powered marketing agency, and Waltz Health’s drug-pricing/access technology. These moves position the platform for tech-enabled growth across access, pricing, and omnichannel execution.
Market Expansion: Evidence indicates EVERSANA is expanding capacity and reach through a large new distribution center and a merger that extends influence with payers and employers. Ongoing commercialization wins and partnerships show continued entry into adjacent access and pricing markets.
Resilience (National Resilience, Inc.) is a first-of-its-kind manufacturing and technology company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the medicines of today and tomorrow can be made quickly, safely, and at scale
Resilience (resilience.com).'s Top Stability & Growth Strengths
Investor Backing & Capital Strength: The company is described as well-funded, with multiple sizable financing events including up to $825M in long-term financing to accelerate its CDMO strategy and prior large equity rounds. Public-sector funding and government-backed initiatives are also cited as signals of confidence in its role in domestic manufacturing and supply-chain resilience.
Strategic Partnerships: The business has landed recognizable relationships such as an AstraZeneca fill/finish deal and earlier work with Takeda, which help validate its capabilities and quality expectations. Additional collaborations with research institutions are positioned as strengthening its advanced-therapy offering.
Future-Ready Strategy: The operating model is oriented toward complex modalities (biologics, vaccines, nucleic acids, cell and gene therapy) with drug substance and fill/finish capabilities, positioning it toward segments expected to remain strategically important. The post-2025 pivot toward a smaller set of “go-forward” hubs is framed as a refocus on higher-demand areas like sterile drug product and selected biologics/cell-therapy capabilities.
For over 240 years, Takeda’s propensity to evolve has driven the next generation of innovation, and as a future-focused organization, we’re continuing to drive forward with endurance in our steadfast pursuit to achieve the best outcomes for our patients in a rapidly changing world. We have been preparing for this period of value creation by investing in data, digital and...
Takeda's Top Stability & Growth Strengths
Strong Market Position & Advantage: Market position is reinforced by being the largest pharmaceutical company in Asia, a consistent top‑15–20 global player by revenue, and operations across roughly 80 countries.
Innovation-Driven Growth: Innovation momentum is evident through a first‑in‑class FDA‑approved narcolepsy treatment and positive late‑stage results for oveporexton and zasocitinib. Multiple priority reviews and planned launches further support the pipeline.
Profitability: Profitability is strengthening with a sharp increase in net profit and a significant rise in operating profit, accompanied by an upgraded full‑year outlook. Cost discipline and transformation initiatives are also helping protect earnings while investment rises.
AstraZeneca is a global, science-led, patient-focused biopharmaceutical company committed to excellence in the research, development, and commercialization of prescription medicines. With approximately 90,000 employees across 85 countries, the company aims to unlock the power of science to deliver innovative medicines that transform patient outcomes and improve healthcare for people, society, and the planet worldwide.
